Ortho Clinical Diagnostics Unveils Next-Gen Analyzer at Lab Show
|
By LabMedica International staff writers Posted on 02 Aug 2018 |
|
Image: The VITROS XT 7600 Integrated System (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA), a global in vitro diagnostics company, officially unveiled the VITROS XT 7600 Integrated System at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. Ortho also displayed additional clinical lab and immunohematology analyzers and other solutions at the conference held July 29 - August 2 in Chicago, Illinois, USA. Additionally, the company presented seven scientific posters highlighting the performance of assays that are part of its offerings for sepsis, Chagas, diabetes and other conditions.
Ortho is a global in vitro diagnostics company serving the clinical laboratory and immunohematology communities. The company provides sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories. Ortho's blood typing products for the immunohematology community help ensure that every patient receives safe, right type and right unit of blood.
On display at this year’s AACC was Ortho's latest analyzer to receive CE Mark, the VITROS XT 7600 Integrated System, which combines proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously. Other products displayed by Ortho at the event included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions and its immunohematology analyzers, ORTHO VISION and ORTHO VISION Max. Visitors at the company’s booth also explored its virtual reality experience LabBuilder, which allows users to re-imagine what is possible by creating a digital lab that fits their needs.
"Ortho is committed to innovation that helps our customers achieve their goals of enhancing medical value while increasing efficiency," said Robert Yates, chief operating officer for Ortho. "We're delighted to officially reveal at AACC Ortho's VITROS XT 7600, which introduces fundamental change to the way labs operate, and to present insightful posters in the areas of cardiology, infectious disease and endocrinology."
Ortho is a global in vitro diagnostics company serving the clinical laboratory and immunohematology communities. The company provides sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories. Ortho's blood typing products for the immunohematology community help ensure that every patient receives safe, right type and right unit of blood.
On display at this year’s AACC was Ortho's latest analyzer to receive CE Mark, the VITROS XT 7600 Integrated System, which combines proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously. Other products displayed by Ortho at the event included VITROS 3600 Immunodiagnostic Systems, VITROS 4600 Chemistry Systems, VITROS 5600 Integrated Systems, VITROS Automation Solutions and its immunohematology analyzers, ORTHO VISION and ORTHO VISION Max. Visitors at the company’s booth also explored its virtual reality experience LabBuilder, which allows users to re-imagine what is possible by creating a digital lab that fits their needs.
"Ortho is committed to innovation that helps our customers achieve their goals of enhancing medical value while increasing efficiency," said Robert Yates, chief operating officer for Ortho. "We're delighted to officially reveal at AACC Ortho's VITROS XT 7600, which introduces fundamental change to the way labs operate, and to present insightful posters in the areas of cardiology, infectious disease and endocrinology."
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Automated Urinalysis Solution
UN-9000
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Latest AACC 2018 News
- Mesa Biotech Showcases PCR Testing Platform at Clinical Expo
- Mindray Medical Unveils Chemiluminescence Immunoassay System at AACC 2018
- Abbott Diagnostics Displays Alinity Family of Systems
- Roche Diagnostics Highlights Latest Clinical Lab Solutions at AACC
- Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology
- Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers
- Thermo Fisher Scientific Showcases Product Portfolio at Lab Trade Show
- EKF Diagnostics Highlights Assay Kit and POC Analyzer at AACC 2018
- Randox Laboratories Showcases Advances in Biotechnology at Clinical Lab Expo
- Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio
- Beckman Coulter Features New Hematology Analyzers and Lab Automation
- Carolina Liquid Chemistries Promotes Family of Clinical Chemistry Analyzers
- Orion Diagnostica Showcases Rapid Test and Molecular Platform at Lab Show
- Saladax Biomedical Launches Game-Changing Assays at AACC 2018
- SeraCare Life Sciences Promotes New AccuSpan Panel at Lab Expo
- Sekisui Diagnostics Showcases Clinical Chemistry and Immunoassay Analyzers
Channels
Clinical Chemistry
view channel
Blood Protein Panel Detects ALS with High Accuracy
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that affects the nerve cells responsible for muscle movement. Early symptoms, including muscle weakness, cramps, and difficulty... Read more
Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
Chronic inflammation can persist for months or years when immune cells continue attacking tissues despite the absence of an active threat. It is associated with cancers, brain disorders, autoimmune diseases,... Read more
Molecular Diagnostics
view channel
New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma
Arima Genomics (Carlsbad, CA, USA) will present new research highlighting the expanding clinical applications of its Aventa FusionPlus and Aventa Lymphoma tests at the Association for Molecular Pathology... Read more
Comprehensive Tumor Profiling Uncovers Overlooked Hereditary Cancer Risk Genes
Patients with solid tumors often undergo molecular profiling to identify alterations that can guide therapy. This testing may also reveal constitutional cancer-predisposing DNA variants, which are present... Read more
Hematology
view channel
New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more
Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more
Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read moreMicrobiology
view channel
Common Genetic Variant Increases Risk of Bacterial Pneumonia
Pneumonia is a common and sometimes serious infection, with 20,000–30,000 people affected in Sweden each year. Known risk factors include advanced age, smoking, and underlying medical conditions.... Read more
Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more
Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more
Pathology
view channel
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Technology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read more
Industry
view channel
Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
Siemens Healthineers has begun carving out its in vitro diagnostics business, which will operate as Olyrian Diagnostics. The new name will be introduced in stages as the business prepares to become a standalone... Read more
Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences applications. The transaction involved a cash payment of USD 240 million... Read more
New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more